Results 141 to 150 of about 10,714 (176)

Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies

Acta Pharmaceutica Sinica B, 2021
Xiao-Feng Xiong, Yang Sun, Zhendong Song   +2 more
exaly  

Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment

Current Opinion in Chemical Biology, 2021
Trever Bivona, Franziska Haderk, D Lucas Kerr   +2 more
exaly  

SHP2 INHIBITORS

2021
CIAMMAICHELLA ALINA, FERRIGNO FEDERICA, ONTORIA ONTORIA JESUS MARIA, PETROCCHI ALESSIA, PONZI SIMONA, ROSSETTI ILARIA, SFERRAZZA ALESSIO, TORRENTE ESTHER   +7 more
openaire   +4 more sources

Engineered Extracellular Vesicles with SHP2 High Expression Promote Mitophagy for Alzheimer's Disease Treatment

Advanced Materials, 2022
Chao Wang
exaly  

Targeting SHP2 as a therapeutic strategy for inflammatory diseases

European Journal of Medicinal Chemistry, 2021
Hua Li, Lixia Chen, Dejuan Sun
exaly  

Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders

European Journal of Medicinal Chemistry, 2021
Hanlin Wang, Bing Zhou, Yaxi Yang
exaly  

Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020)

Current Medicinal Chemistry, 2021
Guilong Zhao, Huan Zhang
exaly  

INHIBITORS OF SHP2

2021
SCHOMBER TIBOR, BRÜGGEMEIER ULF, BECKER MICHAEL, PIRKULIYEVA SONA   +3 more
openaire   +1 more source

The First SHP2 PROTAC

Synfacts, 2020
openaire   +1 more source

Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders

European Journal of Medicinal Chemistry, 2020
Hong-Min Liu, Bin Yu, Kai Tang
exaly